smith and nephew acquisition

Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

This strategic acquisition represents a significant opportunity to strengthen Smith+Nephew's position in a high-value area and allows us to offer a leading extremities portfolio to customers.". The acquisition supports Smith+Nephew’s strategy to invest in higher-growth segments. This strategic acquisition represents a significant opportunity to strengthen Smith+Nephew’s position in a high-value area and allows us to offer a leading extremities portfolio to customers.”. S mith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire the Extremity Orthopaedics business of Integra LifeSciences Holdings Corporation (NASDAQ:IART) for $240 million. Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire the Extremity Orthopaedics business of Integra LifeSciences Holdings Corporation (NASDAQ:IART) for $240 million. The business operates from facilities in Austin, Texas, which includes a surgeon training facility, as well as in Lyon, France. Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces completion of the acquisition of Osiris Therapeutics, Inc. for $19.00 per share in cash, representing a total equity value of approximately $660 million. The portfolio is highly complementary to Smith+Nephew's existing orthopaedics offering, in particular providing entry into the shoulder replacement and foot and ankle segments. For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on Twitter, LinkedIn or Facebook. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). Smith & Nephew has acquired 33 companies, including 11 in the last 5 years. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature.

Smith & Nephew has more than 16,000 employees and a presence in more than 100 countries. For more information, please read our Privacy Policy. This information is provided by RNS, the news service of the London Stock Exchange. Acquiring Organization: Smith & Nephew Smith and Nephew is a manufactures and markets orthopedic devices, sports medicine and ENT technologies. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas®, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru®. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. The US extremities segment has been growing at around 6-7% per annum (1) . Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. ◊ Trademark of Smith+Nephew. We are excited for the opportunities ahead as we continue to advance orthopaedic innovations for our customers and improve patient outcomes.". The Extremity Orthopaedics R&D pipeline includes a next-generation shoulder replacement system, which is expected to be ready for full commercial launch in 2022. The business is expected to deliver double-digit revenue growth and be slightly dilutive to trading profit in 2021 and 2022. This acquisition will significantly strengthen Smith+Nephew’s extremities business by adding a combination of a focused sales channel, complementary shoulder replacement and upper and lower extremities portfolio, and an exciting new product pipeline. Certain marks registered US Patent and Trademark Office.

Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel(R) , Bactiseal(R) , Cadence(R) , Certas(R) , Codman(R) , CUSA(R) , DuraGen(R) , DuraSeal(R) , ICP Express(R) , Integra(R) , MediHoney(R) , MicroFrance(R) , PriMatrix(R) , Salto Talaris(R) , SurgiMend(R) , TCC-EZ(R) , Titan(TM) and VersaTru(R) .

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Peter Ligotti, Senior Vice President, Extremity Orthopaedics, Integra LifeSciences, said: "We are looking forward to joining an organisation that is committed to growing and expanding its orthopaedic product portfolio.

Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Investors Andrew Swift Smith & Nephew +44 (0) 20 7960 2285 Media Charles Reynolds Smith & Nephew +44 (0) 1923 477314 Ben Atwell / Andrew Ward FTI Consulting +44 (0) 20 3727 1000 17 April 2019.

Brazil Vs Colombia Coffee, Cardi B - Bodak Yellow Mp4, What Is The Main Message Of The Book Of Hebrews?, Steven Stamkos Contract, Csk Vs Rr, Sketch Comedy Shows 2019, Weather Today, Avanti Pizza Santa Cruz, The Running Man 2019, Argentina Vs England, George Halas, Le'veon Bell Contract, Melbourne Cbd Hotels, Andrea Ranocchia, Corey Crawford, I Like It Lyrics, Crystal Visions Lyrics, Norway Economy Problems, Hattie Feedback, Emma Watson Husband 2020, Boxrec Greatest Of All Time, Mississauga Chargers, Long Gone By Movie Review, Send My Love To Your New Lover Chords, Anime Car Stickers, Kieron Pollard Ipl, Out Of The Blue, Kelly Ripa Net Worth 2020, Team Leader Feedback Examples, Minnesota Kitchen Remodel, Jennifer Meyer Family, St Thomas' Hospital Baby Unit, Sadio Mane Wife, Lukas Meaning, Does Kristen Stewart Have Instagram, Half-life: Alyx System Requirements, Ring Indoor Cam Mini 2pk Review, Kuwait Time, Simple Feedback Form, Cass Mapother, Shop Now Or Learn More, Among Friends (2012), Sweet Caroline, Reggie Bush Heisman, Braxton Berrios Height And Weight, Italy Population Per Square Mile, Remake Of Bonanza, Woody Harrelson, Battle Of The Dragon Lyrics, Meet The Richardsons Review,